{
    "nctId": "NCT06433609",
    "briefTitle": "Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer",
    "officialTitle": "A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 131,
    "primaryOutcomeMeasure": "ORR (objective response rate) by investigator",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. 18 years to 75 years old (including boundary values), female patients with breast cancer;\n2. ECOG PS Score: 0\\~1;\n3. Histologically or cytologically confirmed HER2-negative advanced breast cancer;\n4. Disease progression after prior 1-2 lines of systemic therapy; if HR-positive, prior CDK4/6 inhibitor is necessary;\n5. Based on RECIST v1.1, at least one measurable lesion;\n6. Brain metastasis with no clinical symptoms, or treated, stable brain metastases are eligible;\n7. No prior PD-(L)1 inhibitor;\n8. Patients must have a life expectancy \u2265 6 months;\n9. Adequate organ function and marrow function (no corrective treatment within 14 days before first dose);\n10. Patients of childbearing potential should have a negative urine or serum pregnancy, and must promise to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy or be celibate;\n11. Available blood samples for ctDNA detection in the exploratory study;\n12. Willing and able to provide written informed consent and comply with the requirements and restrictions in the protocol.\n\nExclusion Criteria:\n\n1. Has known active brain metastasis which needs local therapy immediately;\n2. Prior anti-HER2 or anti-TROP-2 treatment;\n3. Has received or been receiving PD-(L)1 inhibitors and/or ADC containing a topoisomerase inhibitor-like payload;\n4. Existence of third space fluid that is not well controlled by effective methods, e.g. drainage;\n5. Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy or immunological therapy within 4 weeks before first dose of study therapy; has received antitumor endocrine therapy within one week before first dose of study therapy;\n6. Use of other antitumor systemic treatment during the study;\n7. Has active autoimmune disease or a history of autoimmune disease;\n8. Known history of immunodeficiency, including HIV-positive, other acquired or innate immunodeficient disease, or known history of organ transplantation;\n9. Has active hepatitis B (HBsAg-positive and HBV DNA\u2265500 IU/mL), hepatitis C (positive for HCV antibody and HCV RNA above ULN) and hepatic cirrhosis;\n10. Has an active infection requiring antibiotics, antiviral or antifungal treatment, or pyrexia \\>38.5\u2103 of unknown origin during the screening period before first dose of study therapy (patients with pyrexia due to cancer could be enrolled determined by investigator);\n11. Receiving immunosuppressive medication, or systemic corticosteroid therapy for the purpose of immunosuppression (prednisone at \\>10mg/d or equivalent dose of other corticosteroids), and continuous use within 2 weeks before the first dose of study therapy;\n12. Other malignancy within prior 5 years unless curatively treated with no evidence of disease for at least recent 3 years, except: curatively treated in situ cancer of the cervix, skin basal cell carcinoma or skin squamous cell carcinoma;\n13. Hypersensitivity to study therapy or any of its excipients;\n14. Has known clinically significant lung disease, including but not limited to: interstitial lung disease, pneumonitis, pulmonary fibrosis;\n15. Known history of uncontrolled cardiovascular clinical symptom or disease that is not well controlled;\n16. Has received a live vaccine within 4 weeks before first dose of study therapy, or potential to receive a live vaccine during the trial treatment;\n17. Patients with a positive serum or urine pregnancy test or who are breastfeeding; patients of childbearing potential who are unwilling or not available to use an effective method of contraception;\n18. Other conditions that might influence the study and analysis of results in the opinion of the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}